title: In reply to 'discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome'.
authors.affiliation: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
authors.forename: Gianluigi
authors.initials: G
authors.lastname: Ardissino
authors.affiliation: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
authors.forename: Ilaria
authors.initials: I
authors.lastname: Possenti
authors.affiliation: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
authors.forename: Francesca
authors.initials: F
authors.lastname: Tel
mesh_terms: D061067:Antibodies, Monoclonal, Humanized; D065766:Atypical Hemolytic Uremic Syndrome; D017281:Cost of Illness; D064420:Drug-Related Side Effects and Adverse Reactions / Q000517:prevention & control*; D005260:Female; D006456:Hemoglobinuria; D006801:Humans; D008297:Male; D011788:Quality of Life; D028761:Withholding Treatment
chemical_list: D061067:Antibodies, Monoclonal, Humanized